Researchers believe combining navitoclax with ruxolitinib should help individuals with myelofibrosis. During this demo 50 % the individuals have navitoclax and ruxolitinib. Another 50 % have ruxolitinib in addition to a dummy drug (placebo ). The content material printed in Cureus is the result of scientific expertise and/or research by https://sn-3877643.nizarblog.com/26244638/mouse-an-overview